Acquisition Target CTL has been acquired by VION Biosciences as of April 2026, signaling a shift in strategic direction and potential continuity or expansion of immunoassay capabilities. This creates opportunities to approach VION’s integration teams or CTL legacy accounts for cross-sell of ImmunoSpot kits, analyzers, and cryopreserved PBMC libraries.

Global Client Base With over 2,000 global clients across academia and industry and a CLIA-certified, GLP-compliant facility, there is substantial cross-sell potential for expanded immune monitoring services, additional assay formats, and training programs to existing users of ELISPOT, ELISA, FACS, and related platforms.

Comprehensive Portfolio CTL offers a broad suite from consumables and reference PBMC libraries to automated data analysis and multi-color FluoroSpot capabilities. This enables multi-product bundles and integrated solutions for customers seeking end-to-end immune monitoring workflows.

Facility Scale Processing up to 450 samples per week in a GLP-compliant lab highlights capacity for large studies and CRO partnerships. This capacity can be marketed to sponsors needing scalable immune monitoring services for clinical trials and translational research.

Digital & Training Leverage A robust tech stack including ImmunoSpot analyzers, BioSpot instruments, and comprehensive training offerings presents upsell opportunities for software licenses, data analysis subscriptions, and hands-on workshops to both new and existing customers.